drugset / Trial / NCT00964171
Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well efavirenz works as second-line therapy in treating patients with metastatic pancreatic cancer.
Timeline
- Start
- 2008-08
- Primary completion
- 2010-07
- Completion
- 2010-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efavirenz | Other / unclassified | 600 mg | Oral |